s i o n may o c c u r . I n A u s t r i a a nationwide s c r e e n i n g f o r b i o t i n i d a s ed e f i c i e n c y was s t a r t e d i n Jan.l986:325672newborns have been screened on t h e i r f i l t e r -p a p e r blood samples,out of t h e s e i n 10 p a t i e n t s t h e d i g n o s i s b i o t . d e f . h a s been made by a enzymatic-spect r o p h o t o m e t r i c method o f Knappe.Thus,the i n c i d e n c e i n A u s t r i a i s 1:32567;data from a worldwide s c r e e n i n g r e p o r t on an i n c i d e n c e o f 1:61067.The mean b i o t i n i d a s e a c t i v i t y has been c a l c u l a t e d t o be 0,40+0,12nmol/min/mlpl. (normal range:4,01-7.98)this i s 6,1+2,46of t h e mean normal a c t i v i t y . 6 p a t i e n t s were c l a s s i f i e d a s "profound" and b p a t i e n t s a s p a r t i a l -d e f i c i e n t . I n regard t o t h e r a p e u t i c r egimes we t r e a t e d o n l y t h e s e p a t i e n t s with a b i o t . d e f . l e s s t h a n 10%of mean normal a c t i v i t y . (n=6/10mgbiotin/d) .The group o f c h i l dren w i t h p a r t i a l d e f . i s under c o n t r o l up t o now.Recently i t has been p u b l i s h e d t h a t a l s o c h i l d r e n with a r e s i d u a l a c t i v i t y betw. 1 0 + 3 0~~s h o u l d be t r e a t e d . D u e t o r e c e n t knowledge c l i n i c a l symptoms can be avoided and r e v e r s e d by means o f e a r l y treatment(5-l0mg b i o t i n / d ) . T h e r e f o r e a neonatal s c r e e n i n g seems t o be h i g h l y j u s t if i e d and e a r l y t r e a t m e n t o f a l l p a t i e n t s i s c l e a r l y i n d i c a t e d . Ep is the primary hormone responsible for erythrocyte production throughout development. It has been proposed that recombinant human Ep f mEp) k used for the u e m e n t of anemia in premature h m a n neonates. Before doing so, it is impnant to examine pharmacokineuc panmeters during development in animals. To do so we developed a sensitive and specific mEp immunoprecipitation assay using plyclonal antisera. A nonsompanmental approach was employed to determine phannacokinetic in the FET and NB groups (Table) . We elimination and l m e distribution volume. For mEp to k effective in the treaunent of anemia in prematu% neonates, it is likely h a t large; M p doses per kg than those used in mating anemic adult patients will be needed.
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SERUM IMMUNOREACTIVE ERYTHROPOIETIN IN CHILDREN WITH ACUTE LEUKAEMIA AT VARIOUS STAGES OF DISEASE, AN0 THE EFFECTS OF TREATMENT. M a r i t H e l l e b o s t a d ( l ) , J e n s Mar-
43 s t r a n d e r ( l ) , Sophie H. S l e r d a h l ( Z ) , P. Mary Cotea(3!, Harald E. Refsum(4). 1 ) Dept. o f P a e d i a t r i c s , U l l e v a l H o s p i t a l , O s l o , Norway, 2 ) Dept. o f P a e d i a t r i c s , Riksh o s p i t a l e t , Oslo, Norway, 3) C l i n i c a l Research C e n t r e , Harrow, Middx., U.K., 4 ) L a b o r a t o r y a f C l i n i c a l Physiology, U l l e v i l Hoapit a l , Oslo, Norway.
Most c h i l d r e n w i t h leukaemia a r e anaemic a t t h e t i m e o f diagnosis and a t v a r i o u s t i m e s d u r i n g t r e a t m e n t . Serum e r y t h r o p o i e t i n (EPO) was e s t i m a t e d by a radioimmunoasaay method i n 27 c h i l d r e n w i t h a c u t e leukaemia (~2 6 )
o r lymphoma (n:l) a t d i a g n o s i s ( n = 1 6 ) , i n r e l a t i o n t o h i g h d o s e m e t h o t r e x a t e (MTX, n r l l ) o r c y t o s i n e a r ab i n o s i d e (Ara-C, n:8), and d u r i n g o r a l maintenance t h e r a p y w i t h MTX and 6-mercaptopurine (n-10). At d i a g n o s i s serum EPO was i nc r e a s e d i n t h e c h i l d r e n w i t h anaemia, and i n v e r s e l y r e l a t e d t o haemoglobin (Hb, pL0.00005) . A f t e r high dose M T X , i n some c h i l d r e n serum EPO i n c r e a s e d where Hb was unchanged o r i nc r e a s e d . A f t e r h i g h d o s e Ara-C Hb d e c l i n e d , and serum EPO i n c r e as e d markedly i n a l l c a s e s . During o r a l maintenance t h e r a p y when Hb was i n t h e normal r a n g e , serum EPO was s l i g h t l y i n c r e a s e d i n some c h i l d r e n . I n c o n c l u s i o n , c h i l d r e n w i t h leukaemia respond t o anaemia w i t h an i n c r e a s e i n serum EPO c o n c e n t r a t i o n , b u t i n r e l a t i o n t o t r e a t m e n t w i t h h i g h d o s e MTX and Ara-C, a d d i t i o n a l mechanisms may i n f l u e n c e t h e EPO c o n c e n t r a t i o n .
ADENOSINE ACCUMULATION IN HEMORRHAGIC C E R E -
B R O S P I N A L FLUID. G. V a n d e n B e r g h e , S. S t e v e n s , J . V a n h o v e & J. J a e k e n , Department of Pediatrics. University 44 Hospital Gasthuisberg. Leuven. Belgium.
Although adenosine (Ado) m a y play a critical regulatory role in brain, little information is available with r e s p e c t to its metabolism in cerebrospinal fluid (CSF). In normal, cell-free C S F from children of various a g e s , degradation of 1 FM Ado r e a c h e d only 0 . 0 2 8 2 0 . 0 1 0 nmol/h/ml a t 25 O C ( m e a n 2 S E M for n = 9). Both However, incubation of a hemolysate with CSF resulted in buildup of A d o a t r a t e s that w e r e proportional t o both a m o u n t of hemolysate and of C S F . Accumulation w a s e n h a n c e d in t h e p r e s e n c e of t h e a d e n o s i n e deaminase inhibitor deoxycoformycin (1pM). Further s t u d i e s s h o w e d t h a t CSF c o n t a i n s a 5'-nucleotidase (activity : 7.4 f 1.8 nmol/hlml a t 25 OC, n = 1 1 ) w~t h t h e kinetic characteristics of a n ecto-5'-nucleotidase (high affinity for AMP, inhibition by adenosine 5'-m e t h y l e n e d i p h o s p h o n a t e , n o stimulation b y 2 , 3 -b i s p h o s p h o g l y c erate). It is concluded that Ado m a y a c c u m u l a t e in hemorrhagic CSF as a result of t h e combination of r e d cell hemolysis providing AMP, t h e p r e s e n c e of a membrane-derived 5'-nucleotidase, a n d t h e low activity of a d e n o s i n e d e a m i n a s e . 46 Reiner ~e n z l , Walter H.Teller Depts. P e d i a t r i c s I and l~y n e c o l o g y , U n i v e r s i t y o f Ulm, D-7900 Ulm, FRG During g e s t a t i o n human c h o r i o n i c gonadotropin (hCG) i s s e c r e t e d i n an i n i t i a l r i s e t o m a i n t a i n corpus luteum f u n c t i o n . I n e a r l y pregnancy, a l s o spontaneous p u l s i t i l e hCG s e c r e t i o n r e g u l a t e d by a GnRH-like compound o f p l a c e n t a l o r i g i n has been d e s c r i b e d . -Q u e s t i o n : Are t h e r e m e t a b o l i c i n f l u e n c e s which r e g u l a t e s hCG r el e a s e ? -Methods: E x p l a n t s o f human cerm p l a c e n t a (500 mg) were p e r i f u s e d i n 1 ml chambers (ACUSYST, E n d o t r o n~c s ) w i t h a flow r a t e of 100 u l medium 199/min. The glucose c o n c e n t r a t i o n s were changed from 5.55 t o 0 mmol/l r e s p . 16.0 t o 5.55 mmol/l i n p u l s e s of 16 min. The experiments l a s t e d f o r 5 hours. HCG was measured e v e r y 4 min by IRIMA. -R e s u l t s : 1. I n hypoglycemic c o n d i t i o n s , the lowered g l u c o s e c o n c e n t r a t i o n was followed by s i g n i f i c a n t peaks (PULSAR a n a l y s i s ) of hCG reaching more t h a n 40.9'25.2 % (mean + SD) o f b a s a l l e v e l ( d u r a t i o n 6.1'1.8 min) (n=13). 2 . Repeated lowering of g l u c o s e (max. 3 times) showed c o r r e s p o n d i n g hCG b u r s t s ( h e i g h t : 16 -168 mIU/ml). 3 . Decreasing g l u c o s e conc e n t r a t i o n s i n r e r i f u s a t e p e r s e were answered by e l e v a t e d hCG b u r s t s (n=3).-Conclusion: I n v i t r o , human p l a c e n t a r e a c t s t o d iminished g l u c o s e s u p p l y w i t h i n c r e a s e d hCG r e l e a s e . T h i s does n o t seem t o be due t o a t o t a l l a c k of fuel.-Supp. by DFG (He110712-3) 
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